Medpace Holdings Inc
NASDAQ:MEDP

Watchlist Manager
Medpace Holdings Inc Logo
Medpace Holdings Inc
NASDAQ:MEDP
Watchlist
Price: 342.69 USD 1.07% Market Closed
Market Cap: 10.7B USD
Have any thoughts about
Medpace Holdings Inc?
Write Note

Medpace Holdings Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Medpace Holdings Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Medpace Holdings Inc
NASDAQ:MEDP
Net Income (Common)
$365.6m
CAGR 3-Years
26%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.1B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.9B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
4%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
9%
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
42%
CAGR 10-Years
15%
No Stocks Found

Medpace Holdings Inc
Glance View

Market Cap
10.6B USD
Industry
Life Sciences Tools & Services
Economic Moat
Wide

Medpace Holdings Inc., a name renowned in the clinical research sector, operates at the heart of the drug development process. Founded in 1992 by Dr. August Troendle, Medpace carved a niche for itself as a full-service clinical contract research organization (CRO). The essence of its operation lies in managing the complex journey of bringing new pharmaceuticals and medical devices from conception through to approval. Medpace partners with various biopharmaceutical companies to design, conduct, and oversee clinical trials, aligning with regulatory requirements to ensure these products are safe and effective. The company stands out by offering a comprehensive suite of services, including strategic consulting, project management, and the integration of cutting-edge technologies—a holistic approach that often distinguishes it from competitors. The engine driving Medpace’s profitability is its model of operational excellence fueled by its disciplined and integrated approach. The company generates revenue primarily from the contracts it secures with sponsors for conducting each phase of clinical trials. By closely collaborating with its clients, Medpace ensures tailored solutions that operate under specified timelines and budgets, enhancing client retention and attracting new business. What truly underlines Medpace’s financial success is its ability to deliver high-quality results, evidenced by robust data captured during trials and the attainment of key endpoints. This reputation for quality not only nurtures client trust but also consolidates Medpace's standing as a pivotal player in the CRO industry, securing a sustainable revenue stream and ongoing growth in a competitive landscape.

MEDP Intrinsic Value
288.64 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Medpace Holdings Inc's Net Income (Common)?
Net Income (Common)
365.6m USD

Based on the financial report for Sep 30, 2024, Medpace Holdings Inc's Net Income (Common) amounts to 365.6m USD.

What is Medpace Holdings Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
31%

Over the last year, the Net Income (Common) growth was 34%. The average annual Net Income (Common) growth rates for Medpace Holdings Inc have been 26% over the past three years , 31% over the past five years .

Back to Top